INMB Inmune Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INMB

Price (delayed)

$2

Market cap

$55.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.67

Enterprise value

$38.5M

?
Relative Growth: Rel. Growth: 30
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 12

INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that ...

Highlights
The EPS has soared by 73% year-on-year and by 60% since the previous quarter
Inmune Bio's net income has surged by 67% YoY and by 56% QoQ
INMB's equity is down by 29% year-on-year but it is up by 3.8% since the previous quarter
The revenue has dropped by 100% year-on-year
The gross profit has shrunk by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inmunebio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of INMB

INMB stock price

How has the Inmune Bio stock price performed over time
Intraday
-7.41%
1 week
-2.44%
1 month
-13.79%
1 year
0.5%
YTD
28.21%
QTD
22.7%

Financial performance

How have Inmune Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.2M
Net income
-$18.42M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% year-on-year
The gross profit has shrunk by 100% YoY
Inmune Bio's net income has surged by 67% YoY and by 56% QoQ
The company's operating income has surged by 64% YoY and by 53% QoQ

Price vs fundamentals

How does INMB's price correlate with its fundamentals

Growth

What is Inmune Bio's growth rate over time

Valuation

What is Inmune Bio stock price valuation
P/E
N/A
P/B
2.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 73% year-on-year and by 60% since the previous quarter
The P/B is 48% higher than the last 4 quarters average of 1.9 but 9% lower than the 5-year quarterly average of 3.1
INMB's equity is down by 29% year-on-year but it is up by 3.8% since the previous quarter
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Inmune Bio business performance
INMB's ROA has soared by 53% YoY and by 52% QoQ
Inmune Bio's ROE has soared by 52% YoY and by 51% from the previous quarter

Dividends

What is INMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INMB.

Financial health

How did Inmune Bio financials performed over time
The total assets is down by 29% YoY but it is up by 4% QoQ
The total liabilities fell by 26% YoY but it rose by 4.7% QoQ
The debt is 93% smaller than the equity
INMB's equity is down by 29% year-on-year but it is up by 3.8% since the previous quarter
The debt to equity has declined by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.